Found 517 results
Author [ Keyword(Asc)] Title Type Year
Filters: Author is Ho, Emily  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Humans
Song Y, Chung CS, Bruno RS, Traber MG, Brown KH, King JC, Ho E.  2009.  Dietary zinc restriction and repletion affects DNA integrity in healthy men.. Am J Clin Nutr. 90(2):321-8.
Wang R, Löhr CV, Fischer K, W Dashwood M, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH.  2013.  Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.. Int J Cancer. 132(5):1004-12.
Beaver LM, Yu T-W, Sokolowski EI, Williams DE, Dashwood RH, Ho E.  2012.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.. Toxicol Appl Pharmacol. 263(3):345-51.
Chen Y-S, Wang R, Dashwood W-M, Löhr CV, Williams DE, Ho E, Mertens-Talcott S, Dashwood RH.  2017.  A miRNA signature for an environmental heterocyclic amine defined by a multi-organ carcinogenicity bioassay in the rat.. Arch Toxicol. 91(10):3415-3425.
Myzak MC, Tong P, Dashwood W-M, Dashwood RH, Ho E.  2007.  Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.. Exp Biol Med (Maywood). 232(2):227-34.
Palomera-Sanchez Z, Watson GW, Wong CP, Beaver LM, Williams DE, Dashwood RH, Ho E.  2017.  The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.. J Nutr Biochem. 47:113-119.
Beaver LM, Kuintzle R, Buchanan A, Wiley MW, Glasser ST, Wong CP, Johnson GS, Chang JH, Löhr CV, Williams DE et al..  2017.  Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer.. J Nutr Biochem. 42:72-83.
Ho E, Song Y.  2009.  Zinc and prostatic cancer.. Curr Opin Clin Nutr Metab Care. 12(6):640-5.
Wong CP, Hsu A, Buchanan A, Palomera-Sanchez Z, Beaver LM, E Houseman A, Williams DE, Dashwood RH, Ho E.  2014.  Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells.. PLoS One. 9(1):e86787.
HT29 Cells
Wang R, Löhr CV, Fischer K, W Dashwood M, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH.  2013.  Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.. Int J Cancer. 132(5):1004-12.
Homeostasis
Beaver LM, Nkrumah-Elie YM, Truong L, Barton CL, Knecht AL, Gonnerman GD, Wong CP, Tanguay RL, Ho E.  2017.  Adverse effects of parental zinc deficiency on metal homeostasis and embryonic development in a zebrafish model.. J Nutr Biochem. 43:78-87.
Histones
Abbas A, J Hall A, Patterson WL, Ho E, Hsu A, Al-Mulla F, Georgel PT.  2016.  Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines.. Biochem Cell Biol. 94(1):71-81.
Myzak MC, W Dashwood M, Orner GA, Ho E, Dashwood RH.  2006.  Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice.. FASEB J. 20(3):506-8.
Ho E, Beaver LM, Williams DE, Dashwood RH.  2011.  Dietary factors and epigenetic regulation for prostate cancer prevention.. Adv Nutr. 2(6):497-510.
Histone Deacetylases
Rajendran P, Kidane AI, Yu T-W, Dashwood W-M, Bisson WH, Löhr CV, Ho E, Williams DE, Dashwood RH.  2013.  HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.. Epigenetics. 8(6):612-23.
Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E.  2006.  Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.. Carcinogenesis. 27(4):811-9.
Rajendran P, Williams DE, Ho E, Dashwood RH.  2011.  Metabolism as a key to histone deacetylase inhibition.. Crit Rev Biochem Mol Biol. 46(3):181-99.
Beaver LM, Yu T-W, Sokolowski EI, Williams DE, Dashwood RH, Ho E.  2012.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.. Toxicol Appl Pharmacol. 263(3):345-51.
Watson GW, Wickramasekara S, Fang Y, Maier CS, Williams DE, Dashwood RH, Perez VI, Ho E.  2016.  HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.. Exp Biol Med (Maywood). 241(11):1177-85.
Histone Deacetylase Inhibitors
Dashwood RH, Ho E.  2008.  Dietary agents as histone deacetylase inhibitors: sulforaphane and structurally related isothiocyanates.. Nutr Rev. 66 Suppl 1:S36-8.
Nian H, Delage B, Ho E, Dashwood RH.  2009.  Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.. Environ Mol Mutagen. 50(3):213-21.
Rajendran P, Williams DE, Ho E, Dashwood RH.  2011.  Metabolism as a key to histone deacetylase inhibition.. Crit Rev Biochem Mol Biol. 46(3):181-99.
Abbas A, J Hall A, Patterson WL, Ho E, Hsu A, Al-Mulla F, Georgel PT.  2016.  Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines.. Biochem Cell Biol. 94(1):71-81.
Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E.  2006.  Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.. Carcinogenesis. 27(4):811-9.
Myzak MC, Tong P, Dashwood W-M, Dashwood RH, Ho E.  2007.  Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.. Exp Biol Med (Maywood). 232(2):227-34.

Pages